ofloxacin has been researched along with Macular Holes in 2 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Equal dosing with topical administration of levofloxacin 0." | 2.72 | Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. ( Lokkila, J; Nurmenniemi, P; Puustjärvi, T; Teräsvirta, M; Uusitalo, H, 2006) |
| "Levofloxacin was detectable 2." | 2.70 | Vitreous penetration of levofloxacin in the uninflamed phakic human eye. ( Groenewald, C; Herbert, EN; McGalliard, J; Pearce, IA; Wong, D, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Puustjärvi, T | 1 |
| Teräsvirta, M | 1 |
| Nurmenniemi, P | 1 |
| Lokkila, J | 1 |
| Uusitalo, H | 1 |
| Herbert, EN | 1 |
| Pearce, IA | 1 |
| McGalliard, J | 1 |
| Wong, D | 1 |
| Groenewald, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Clinical Safety of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%[NCT04212429] | Phase 1/Phase 2 | 128 participants (Anticipated) | Interventional | 2019-09-23 | Recruiting | ||
| The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%[NCT04214821] | Phase 1/Phase 2 | 128 participants (Anticipated) | Interventional | 2019-09-23 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ofloxacin and Macular Holes
| Article | Year |
|---|---|
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Double-B | 2006 |
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Double-B | 2006 |
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Double-B | 2006 |
Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Double-B | 2006 |
Vitreous penetration of levofloxacin in the uninflamed phakic human eye.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; Middle Aged; | 2002 |